Clinical trial

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

NCT04158440

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-04-07

PhasePHASE3

Study timeline

Study start (actual)2020-04-07Date precision: day

Registry last updated2026-07-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Stage II-III Non-small Cell Lung Cancerunresolved

Interventions

4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: ToripalimabDRUG

4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )DRUG

Sponsors & collaborators

Shanghai Junshi Bioscience Co., Ltd.lead sponsor

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04158440 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.